



Incentives for clinicians and CHWs

Jordi Vila

Department of Clinical Microbiology
Hospital Clinic, Barcelona
Spain

Novel Diagnostics for Infectious Diseases, London; March 25-26th

Conflict of interest declaration

I have the following potential conflicts of interest to report

Type of Affiliation / Financial Interest	Name of Commercial Company
Receipt of grants / research supports:	Cepheid, STAT Dx (Qiagen), Astra-Zeneca, ABAC Therapeutics, Shionogi
Receipt of honoraria or consultation fees:	Roche Diagnostics, Siemens, Grifols, Quantum Dx, DeepUII
Participation in a company sponsored speaker's bureau	MSD, Gilead, Becton-Dickinson

Financial incentives based on objectives

Rapid and accurate
microbiological diagnosis

1. Need of rapid microbiology diagnosis

2. Rapid test to diagnose severe infections

3. Clinical Microbiology Laboratory 24/7

1. Need of rapid microbiology diagnosis

Delay in the administration of adequate empiric antibiotic treatment (Sepsis)

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2010, p. 4851-4863
0066-4804/10/\$12.00 doi:10.1128/AAC.00627-10
Copyright © 2010, American Society for Microbiology. All Rights Reserved.

Vol. 54, No. 11

Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Antibiotic Therapy for Sepsis^{v†}

Mical Paul,^{1*} Vered Shani,² Eli Muchtar,² Galia Kariv,² Eyal Robenshtok,² and Leonard Leibovici²

Unit of Infectious Diseases¹ and Department of Medicine E,² Rabin Medical Center, Beilinson Hospital, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Received 6 May 2010/Returned for modification 6 July 2010/Accepted 14 August 2010

oft



CRITICAL CARE

Marquet et al. *Critical Care* (2015) 19:63
DOI 10.1186/s13054-015-0795-y

RESEARCH

Open Access

Incidence and outcome of inappropriate in-hospital empiric antibiotics for severe infection: a systematic review and meta-analysis

Kristel Marquet^{1,2*}, An Liesenborgs², Jochen Bergs³, Arthur Meugels^{1,4} and Neree Claes^{1,5}

tim
init



ELSEVIER

Journal of Infection (2017) 74, 131-141



ELSEVIER

Empiric Antibiotic Treatment Reduces Mortality in Severe Sepsis and Septic Shock From the First Hour: Results From a Guideline-Based Performance Improvement Program*

Ricard Ferrer, MD, PhD¹; Ignacio Martin-Loeches, MD, PhD²; Gary Phillips, MAS³; Tiffany M. Osborn, MD, MPH⁴; Sean Townsend, MD⁵; R. Phillip Dellinger, MD, FCCP, FCCM⁶; [unintelligible] MD, PhD²; Christa Schorr, RN, MSN⁶; Mitchell M. Levy, MD, FCCP, FCCM⁷

Rapid diagnosis



Increased Time to Initial Antimicrobial Administration Is Associated With Progression to Septic Shock in Severe Sepsis Patients

Bristol B. Whiles, BS¹; Amanda S. Deis, MS¹; Steven Q. Simpson, MD²

BIAA
British Infection Association

ial

led. 2006

Attributable mortality of ICU-acquired bloodstream infections: Impact of the source, causative micro-organism, resistance profile and antimicrobial therapy



Kadri SS et al: Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals

Lancet Infectious Diseases 2021; 21: 241


131 hospitals in the USA

21608 patients with bloodstream infections received empirical antibiotic therapy on the day of first blood culture collection

	Concordant empirical antibiotic therapy (n=17 443)	Discordant empirical antibiotic therapy (n=4165)	
Year of admission			
2005-08	4824 (28%)	1041 (25%)	17.7%
2009-11	5943 (34%)	1384 (33%)	18.8%
2012-14	6676 (38%)	1740 (42%)	20.6%

Receiving discordant empirical antibiotic therapy was associated with increased odds of mortality overall, even in patients without sepsis.

Delay in the administration of adequate empiric antibiotic treatment (Hospital pneumonia)



■ inappropriate therapy
□ appropriate therapy

Rapid diagnosis

Impact of the rapid test on therapeutic decisions

- **Current value of rapid ID and AST or resistance determinants**
 - **Earlier appropriate treatment**
 - **Treatment with more narrow spectrum antibiotics**
 - **Reduce antibiotic consumption**
 - **Identify resistance trends to better prevent growth and spread of resistance**
 - **To decide if the patient needs to be isolated**
 - **Decreased the cost of the hospital**

1. Need of rapid microbiology diagnosis

2. Rapid test to diagnose severe infections

Blood


Reduces the time to ID in 22.8 h

Reduces the time to effective treatment in 11.6 h


Impact of MALDI-TOF will be highly dependent on the clinician

- Mortality reduction of 23%
- Mortality reduction of 35% together w/ ASP

Microb Biotechnol (2022) 15: 2667



Detection of the microorganism by MALDI-ToF directly from urine samples



Zboromyrska Y et al: Implementation of a new protocol for direct identification from urine in the routine microbiological diagnosis

Antibiotics 2022; 11: 582

Regarding the 54 cases reliably and positively identified by culture, in 38 cases (70.3%), the patient received adequate empirical therapy and the treatment was not modified, while in 16 cases (29.7%) the treatment was modified, according to the results of direct identification and detection or not of ESBL and/or carbapenemases.

In relation to the empirical treatment in ten cases of the ESBL-producing strains, in four patients ceftriaxone was changed to ertapenem after receiving the results from the Microbiology Department. Two of these four patients were immunosuppressed (a heart transplant patient and a HIV patient) and presented bacteremia from a urinary focus, with the same strain being isolated in the blood culture.

**Vila J, et al. Perspectivas de futuro de la espectrometría de masas
Enfer. Infec. Microb. Clin. 2016; 34 (supl.2): 53**

Direct detection of bacteria from a clinical sample

SAMPLE	GRAM STAIN	DIRECT MALDI-TOF MS ID	CONVENTIONAL CULTURE
Amniotic fluid	GNB	<i>Capnocytophaga sputigena</i>	<i>Capnocytophaga sputigena</i>
Amniotic fluid	GPB	<i>L. monocytogenes</i>	<i>Listeria monocytogenes</i>
Amniotic fluid	GPB	<i>L. monocytogenes</i>	<i>Listeria monocytogenes</i>
Cerebrospinal fluid	Not performed	<i>P. aeruginosa</i>	<i>Pseudomonas aeruginosa</i>
Cerebrospinal fluid	GNB	<i>P. aeruginosa</i>	<i>Pseudomonas aeruginosa</i>
Cerebrospinal fluid	GNB	<i>P. aeruginosa</i>	<i>Pseudomonas aeruginosa</i>
Amniotic fluid	GNB	<i>P. mirabilis</i>	<i>Proteus mirabilis</i>
Amniotic fluid	Streptococci	<i>S. agalactiae</i>	<i>Streptococcus agalactiae</i>
Amniotic fluid	Streptococci	<i>S. agalactiae</i>	<i>Streptococcus agalactiae, Prevotella bivia</i>
Amniotic fluid	Staphylococci	<i>S. aureus</i>	<i>Staphylococcus aureus</i>
Synovial fluid	Streptococci	<i>S. pneumoniae</i>	<i>Streptococcus pneumoniae</i>
Amniotic fluid	GNB	<i>E. coli</i>	<i>Escherichia coli</i>
Bile	Streptococci	<i>E. faecium</i>	<i>Enterococcus faecium</i>
Amniotic fluid	Staphylococci	<i>S. epidermidis</i>	<i>Staphylococcus epidermidis</i>
Amniotic fluid	Streptococci	<i>S. oralis</i>	<i>Streptococcus oralis</i>
Cerebrospinal fluid	No microorganisms	NP	<i>Staphylococcus epidermidis</i>
Peritoneal fluid	No microorganisms	NP	<i>Acinetobacter pittii</i>
Amniotic fluid	Yeast cells	NP	<i>Candida albicans</i>

1. Need of rapid microbiology diagnosis

2. Rapid test to diagnose severe infections

3. Clinical Microbiology Laboratory 24/7

Impact of the rapid test on therapeutic decisions

The Effect of Molecular Rapid Diagnostic Testing on Clinical Outcomes in Bloodstream Infections: A Systematic Review and Meta-analysis

Clinical Infectious Diseases (2017) 64: 15



Enferm Infecc Microbiol Clin (Engl Ed). 2022 Jan;40(1):1-4

Fidalgo B et al: Information delay of significant bloodstream isolates and patient mortality: A retrospective analysis of 6,225 adult patients with bloodstream infection *Clinical Infectious Diseases* 2023; 77: 680

- The aim of this study was to evaluate the clinical and prognostic impact of communicating microbiological information in real time in adult patients with a bloodstream infection
- We have retrospectively reviewed 6,225 clinical episodes of bacteraemia in a 700-bed tertiary teaching hospital from January 2013 to December 2019. Bacteraemia associated mortality was compared between periods where blood culture result was relayed to the infectious disease specialist [IDS] in real time and those periods where information was delayed to the following morning

Bacteraemia aetiology	Dead/Alive	Real-time information Dead/Alive	Delayed Information Dead/Alive	OR	(95% CI)	P-value
All	625/5600	193/1937	432/3663	1.18	(0.99, 1.42)	0.06
Enterobacterales	262/2867	58/957	204/1910	1.76	(1.30, 2.38)	0.00
<i>Pseudomonas aeruginosa</i>	65/466	21/156	44/310	1.05	(0.61, 1.83)	0.85
<i>Staphylococcus aureus</i>	72/430	21/137	51/293	1.14	(0.66, 1.96)	0.65
<i>Enterococcus</i> (<i>E.faecalis</i> and <i>E.faecium</i>)	94/625	32/231	62/394	1.14	(0.72, 1.79)	0.58

The need for a 24/7 hospital coverage for a clinical microbiologist and/or an ID specialist should be revisited in view of the important prognostic implications

CONCLUSIONS

- **There is clinical evidence that rapid identification and determination of the antimicrobial susceptibility of sepsis or pneumonia helps in the implementation of appropriate antimicrobial therapy and, therefore, in reducing mortality**
- **The use of MALDI-ToF mass spectrometry together with the detection of resistant determinants from positive blood or urine cultures has a clinical impact on sepsis and urosepsis**
- **This rapid diagnostic approach will have a greater impact on mortality if the information is provided to the ASP team**
- **A 24/7 microbiological service is essential for the diagnosis of serious infections and microbiologists, physicians and administrators should make joint efforts to establish this service**



T
h
a
n
k
s

jvila@clinic.cat

